Contemporary classification diagnostic and prognosis of primary monoclonal gammopathies (paraproteinemias)
Authors:
A. Sakalová 1; D. Škultétyová 2; Z. Konečná 3; K. Weiglová 4; M. Hrubiško 1; M. Mistrík 5; L. Plank 6
Authors‘ workplace:
Katedra hematológie a transfuziológie Slovenskej zdravotníckej univerzity, Bratislava, 2Národný ústav srdcových a cievnych chorôb, Bratislava, 3Katedra Laboratórnej medicíny Slovenskej zdravotníckej univerzity, Bratislava, 4Medirex s. r. o., biochemické l
1
Published in:
Transfuze Hematol. dnes,16, 2010, No. 4, p. 193-201.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Since the first reports of Waldenström and others (1940), who introduced diagnostics of polyclonal and monoclonal gammopathies based on paper electrophoresis and immunoelectrophoresis and since largest clinical studies of Kyle and co-workers, the concept of primary monoclonal gammopathies has been presently broaded in itsę clinical importance also due to the increased knowledge in molecular genetics. While implementation of immunofixation and Freelite method into biochemical analysis shown major variability of immunoglobuline molecule, histochemical, immunophenotype, cytogenetic and DNA analyses confirmed polymorphisms of plasma cells and their precursors due to genetic and epigenetic factors. The aim of the presented article is to give information on current classification of monoclonal gammapathies, changes in the opinions on the group of monoclonal gammopathies of undetermined significance (MGUS) and malignant gammapathies (multiple myeloma (MM), Waldenström macroglobulinemia (WM), primary systemic AL amyloidosis, in malignant lymphomas). The risk of malignant transformation of MGUS into myeloma in case of paraproteinemia IgG, IgA and into WM in case of IgM, respectively, is highlighted. Biochemical diagnostics of paraproteinemias using Freelite method for kappa/lambda chains of Ig has gained great importance. While immunofixation can be used for precipitation of paraproteins with complete Ig molecule only, Freelite is able to demonstrate also the free chains not bound to IgH epitopes. Biochemical diagnostics of paraproteinemias has role in the early diagnosis of smoldering WM, smoldering, non-secretory and light-chain myeloma and AL amyloidosis. Freelite method was also implemented into the international diagnostic algorithms of these conditions. The following part of the article is aimed for presentation of our experience with diagnostics in cohort of 1182 malignant gammopathies in years 1990–2009 (995 patients with MM, 96 with smoldering myeloma, 58 with WM and 33 with systemic AL amyloidosis). Conclusion: Demonstration of paraprotein, that has incidence of 1–3 % in healthy population at age < 50 years and 7–15 % at age > 70 years has the role of premalignant factor.
Key words:
classification, monoclonal gammopathies, early diagnostics, paraproteinemias
Sources
1. Waldenström J. Diagnosis and treatment of multiple myeloma. Grune Stratton ed., New York, 1970.
2. Whicher JT. Monoclonal proteins. In: Holborow and Reeves WG Immunology in Medicine 2nd Ed. Academic Press, London and New York, 1983; 655: 531-557.
3. Kyle RA, Lust JA. Monoclonal gammopathies of undetermined significance. Semin Hematol 1989; 26: 176-200.
4. Kyle RA, Rajkumar V. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin N Amer 1999; 13: 1181-1202.
5. Adam Z, Tomíška M, Hájek R, et al. Monoklonální gamapatie nejasného významu (benigní monoklonální gamapatie). Vnitř Lék 2000; 46: 286-296.
6. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680.
7. Bradwell AR, Harding SJ, Fournier NJ, et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/λ ratio. Clin Chem 2009; 55: 1646-1655.
8. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-1444.
9. Kyle RA, Child JA, Durie BGM, et al. The International Myeloma Working Group criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
10. Durie BGM, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379-398.
11. Kyle RA, Kumar S. The significance of monoclonal gammopathy of undetermined significance. Haematologica 2009; 94: 1641-1644.
12. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
13. Dispenzieri A, Kyle RA, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-224.
14. Pontet F. A database for 3000 monoclonal immunoglobulin cases and a new classification. Clin Chimica Acta 2005; 355: 13-21.
15. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
16. Dimopoulos M, Kastritis E, Delimpassi S, Zomas A, Kyrtsonis Ch, Zervas K. The International prognostic scoring system for Waldenströmęs macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica 2008; 93: 1420-1422.
17. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
18. Treon S. How I treat Waldenströmęs macroglobulinemia. Blood 2009; 114: 2375-2385.
19. Gertz M, Fonseca R, Rajkumar V. Waldenströmęs macroglobulinemia. Oncologist 2000; 5: 63-67.
20. Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111: 4908-4915.
21. Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
22. Bladé J. Multiple myeloma: diagnosis, staging and criteria of response. Hematology, Education program EHA 2007; 1: 102-107.
23. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenströmęs makroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005; 23: 4662-4668.
24. Sakalová A, Ilenčíková D, Weiglová K, et al. Včasná diagnostika mnohopočetného myelómu – jeho latentných a variantných foriem. Interná Med 2008; 8: 91-97.
25. Chiecchio L, Dagrada GP, Protheroe RK, et al. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica 2009; 94: 1024-1028.
26. Blotta S, Tassone P, Prabhala RH, et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 2009; 114: 3276-3284.
27. Kristinsson S, Björkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden. Blood 2008; 112: 3052-3056.
28. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
29. Bladé J. Diagnostic criteria for MGUS, multiple myeloma and other conditions. N Engl J Med 2006; 355: 2765-2771.
30. Cesana C, Miqueleiz S, Bernuzzi P, et al. Smouldering Waldenströmęs macroglobulinemia: Factors predicting evolution to symptomatic disease. Semin Oncol 2003; 30: 231-235.
31. UK Myeloma Forum: Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681-700.
32. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79: 319-328.
33. Comenzo RA. How I treat amyloidosis. Blood 2009; 114: 3147-3157.
34. Sakalová A, Plank L, Škultétyová D, et al. Primárna amyloidóza obličiek a asymptomatický (smoldering) mnohopočetný myelóm. Interná Med 2009; 9: 338-342.
35. Gameren I, Rijswijk M, Bijzet J, et al. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalisation of serum free light chain. Haematologica 2009; 94: 1094-1100.
36. Sakalová A, Plank L, Škultétyová D, et al. Súčasný pohľad na systémovú AL amyloidózu z hľadiska včasnej diagnózy. Lek Obz 2009; 58: 425-430.
37. Čapek J, Pěnička M, Kment M. Srdeční AL-amyloidóza s relativně benigním průběhem. Prakt Lék 2009; 89: 320-323.
38. Bradwell AR, Carr-Smith HD, Mead GP, et al. Free light chains in patients with Bence Jones myeloma. Lancet 2003; 361: 489-495.
39. Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative serum free light chain assays in clinical practice. Clin Chem 2005; 51: 878-881.
40. Nowrousian MR, Brandhorst D. Free light chain assays are more sensitive than urine IFE in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706-8714.
41. Gertz M, Merlini G, Treon S. Amyloidosis and Waldenströmęs macroglobulinemia Hematology 2004; 257: 1-34.
42. Merlini G, Palladini G. Advances in AL amyloidosis. Hematology Education 2008; 2: 287-293.
43. Rossi F, Petrucci M, Guffanti A, et al. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. Clin Cancer Res 2009; 15: 4439-4445.
44. Koshiol J, Gridley G, Engels E, McMaster M, Landgren O. Chronic immune stimulation and subsequent Waldenström macroglobulinemia. Arch Intern Med 2008; 168: 1903-1909.
45. Wechalekar A, Lachmann H, Goodman H, Bradwell A, Hawkins P, Gillmore J. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008; 112: 4009-4016.
46. Bojtárová E. Transplantácia krvotvorných buniek. Interná Med 2009; 9: 533-538.
47. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009; 94: 270-275.
48. Palumbo A, Sezer O, Kyle R, et al. International myeloma working group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23: 1716-1730.
49. Paiva B, Vidriales M, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017-4023.
50. Sakalová A, Mistrík M, Hrubiško M, et al. Súčasná liečba mnohopočetného myelómu a Waldenströmovej makroglobulinémie. Lek Obzor 2004; 53: 280-284.
51. Hájek R, Adam Z, pro CMG a ČHS. Léčba mnohočetného myelomu: Indikace k léčbě novými léky dle guidelines 2008 České myelomové skupiny 2008 a ČHS. Transfuze Hematol dnes 2008; 14 (Suppl. 2): 37-38.
52. Sakalová A, Dedík L, Škultétyová D, et al. Problém kurability mnohopočetného myelómu. Acta Chemoterapeutica 2006; 16: 32-39.
53. Sakalová A, Chabroňová I, Gažová S, et al. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol 2001; 47: 38-44.
54. Škultéty J., Žiak M., Durdík Š. Zytokinaktivität bei Patienten mit gastrointestinalen Karzinomen. MMW-Taschenbuch: Systemische Enzymtherapie, München, Mediz. Verlag, 2995, s. 251-253.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
![Issue 4](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/6326d7471aee6460fae9bde02f962479.jpeg)
2010 Issue 4
Most read in this issue
- Contemporary classification diagnostic and prognosis of primary monoclonal gammopathies (paraproteinemias)
- Blood donation and iron stores – comparison of double erythrocytapheresis and whole blood donation
-
Radioterapie u folikulárního lymfomu.
Stará historie v nové perspektivě? - Treatment results of chronic myeloid leukemia patients in HOK Olomouc during 2000–2009: the prognostic significance of Sokalęs score and ELN criterions